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OFF-L-dopa dyskinesias have been a surprising side-effect of intrastriatal foetal ventral mesencephalic trans-
plantation in patients with Parkinson’s disease.It has been proposed that excessive and unregulated dopaminer-
gic stimulation of host post-synaptic striatal neurons by the grafts could be responsible for these dyskinesias.
T o address this issue we transplanted foetal dopaminergic neurons from mice lacking the dopamine transporter
(DATKO) or from wild-type mice, into a rat model of Parkinson’s disease and L-dopa-induced dyskinesias. Both
wild-type and DATKO grafts reinnervated the host striatum to a similar extent, but DATKO grafts produced a
greater and more diffuse increase in extra-cellular striatal dopamine levels. Interestingly, grafts containing
wild-type dopaminergic neurons improved parkinsonian signs to a similar extent as DATKO grafts, but provided
a more complete reduction of L-dopa induced dyskinesias. Neither DATKO nor wild-type grafts induced
OFF-L-dopa dyskinesias. Behavioural and receptor autoradiography analyses demonstrated that DATKO grafts
induced a greater normalization of striatal dopaminergic receptor supersensitivity than wild-type grafts. Both
graft types induced a similar downregulation and normalization of PEnk and fosb/Dfosb in striatal neurons.
In summary, DATKO grafts causing high and diffuse extra-cellular dompamine levels do not per se alter graft-
induced recovery or produce OFF-L-dopa dyskinesias.Wild-type dopaminergic neurons appear to be the most
effective neuronal type to restore function and reduce L-dopa-induced dyskinesias.
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3-MT= 3-methoxytyramine; VM=ventral mesencephalic
Received April10, 2008. Revised July 2, 2008. Accepted July 29 , 2008. Advance Access publication November 6, 2008
Introduction
L-dopa-induced dyskinesias (LIDs) are the most disabling
side-effects of pharmacological treatment in patients with
Parkinson’s disease (Fahn, 2003). According to the most
accepted hypothesis, LIDs are caused by the pulsatile, non-
physiological dopaminergic stimulation of denervated
striatal medium spiny neurons during chronic L-dopa
therapy (for review see Olanow et al., 2006). Studies in
the 6-OHDA rat model of Parkinson’s disease have
demonstrated that LID are associated with alterations of
synaptic plasticity in corticostriatal synapses (Picconi et al.,
2003). L-dopa treatment restores striatal long-term poten-
tiation (LTP) lost after dopaminergic denervation, but in
rats with LID these synapses do not depotentiate following
LTP (Picconi et al., 2003). Various pieces of evidence have
linked striatal LTP and synaptic depotentiation with the
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Oh and Chase, 2002). Additionally, these aberrant responses
have been associated with upregulation of preproenkephalin
(PEnk) (Fisher et al., 1991), prodynorphin (PDyn), and
with changes in gene expression of fosB/fosB-related
transcription factors in the post-synaptic striatal neurons
(Cenci et al., 1998; Andersson et al., 1999; Lundblad et al.,
2004; Pavon et al., 2006).
Intrastriatal foetal ventral mesencephalic (VM) trans-
plantation can be effective in improving both parkinsonian
signs and LID in patients with Parkinson’s disease (Lindvall
et al., 1994; Olanow et al., 2003; Mendez et al., 2005). In
rodent models, foetal grafted dopaminergic neurons restore
regulated dopamine (DA) release (Strecker et al., 1987;
Forni et al., 1989; Di Loreto et al., 1996; Stromberg et al.,
2000; Bjorklund and Isacson, 2002), and normalize the
expression of fos/DfosB-related genes, PEnk and PDyn (Lee
et al., 2000; Maries et al., 2006) in striatal areas reinervated
by the graft. These biochemical effects re-establish a
balanced striatal neurotransmission in areas reinervated by
the grafts, which are associated with significant behavioural
improvements (Lee et al., 2000; Steece-Collier et al., 2003;
Maries et al., 2006). Surprisingly, double-blind clinical trials
of human VM transplantation showed lack of efficacy in
some groups of grafted Parkinson’s disease patients, and the
presence of a form of OFF-L-dopa dyskinesia (Freed et al.,
2001; Olanow et al., 2003). It was proposed that excessive
and unregulated production of DA from grafted foetal
neurons affecting non-reinervated striatal areas could be
responsible for the generation of the OFF-L-dopa dyskine-
sias (Freed et al., 2001; Maries et al., 2006), but the
molecular mechanisms underlying these side-effects are not
known. To address this issue we have implanted reuptake-
deficient dopaminergic neurons in the striatum of
6-OHDA-lesioned rats.
The dopamine transporter (DAT) plays a major role in
the regulation of DA handling at striatal synapses, and mice
lacking the DA transporter have a 5-fold increase in basal
striatal extracellular DA levels due to the absence of
reuptake (Jones et al., 1998a). These high levels are possible
because neither degradative enzymes nor other monoamine
transporters can compensate for the lack of reuptake
thereby decreasing the rate of DA clearance from the
extra-cellular space by about 300 times (Jones et al., 1998a).
In this scenario, each DA molecule released has a much
longer diffusion range (up to several milimetres) (Jones
et al., 1998a). Due to this lack of reuptake, and despite an
increased synthesis rate, pre-synaptic DA levels inside the
terminals are510% of normal levels, leading to a dramatic
reduction of the DA pool available for depolarization-
evoked release (Jones et al., 1998a).
In order to investigate the consequences of an excessive
and poorly regulated dopaminergic striatal reinervation
from foetal grafts, we used the transplantation of foetal
VM cells from DATKO mice into the striatum of 6-OHDA-
lesioned, L-dopa-primed dyskinetic rats. Behavioural
studies, in vivo microdialysis, receptor autoradiography
and molecular and histological analyses were carried out to
compare the functional effects of DA replacement therapy
based on the re-introduction of DA synapses with either
a wild-type profile of DA release and uptake, or a situation
in which a disrupted uptake of DA by the implanted
neurons induced high extra-synaptic DA levels in dener-
vated, L-dopa-primed dyskinetic rats.
Material and Methods
Animals
Adult female Sprague–Dawley rats with unilateral 6-OHDA lesions
(medial forebrain bundle injections; Charles River Breeding
Laboratories. Wilmington, MA), were included in this study. All
animal procedures were performed in accordance with the
guidelines of the National Institute of Health and were approved
by the Institutional Animal Care and Use Committee (IACUC) at
McLean Hospital, Harvard Medical School. Animals were housed
according to standard conditions, in a dark/light cycle of 12h,
with ad libitum access to food and water.
Behavioural analysis
Drug-induced rotations
Rotational behaviours in response to amphetamine (4mg/kg i.p),
and apomorphine (0.1mg/kg i.p) were measured prior to
transplantation and at different time-points post-transplantation
(post-tx) (Fig. 1). Rats were randomly placed into plastic bowls
for 90 or 40min (amphetamine or apomorphine tests) and left
and right full-body turns were quantified by a computerized
system. The net rotational asymmetry score was expressed as full-
body turns per minute (Galpern et al., 1996).
Cylinder test
Spontaneous forelimb use was assessed at baseline, 12 and 19
weeks post-tx, using the cylinder test (Schallert, 1999). Animals
were placed in a plastic cylinder and the number of left and right
forepaw contacts with the cylinder wall were counted. Left
(-impaired) forepaw contacts were presented as percentage of
total wall contacts. Lesioned rats showing 420% left forelimb use
before transplantation were excluded.
Dyskinesia scale
Recordings and scoring of abnormal involuntary movements
(AIMs) were performed independently by two trained observers,
blinded to the experimental condition. Abnormal movements were
videotaped at 15, 40, 80 and 120min after L-dopa administration.
For each time point, animal behaviour was recorded for 2min
with the rats in their home cage, and additional 2min with each
rat placed alone in a clean empty rat cage. AIMs were scored
according to a rat dyskinesia scale (Lee et al., 2000). Briefly,
four different dyskinetic behaviours; orolingual dyskinesias
(choreo-athetoid movements of jaw and tongue), limb dyskinesias
(choreo-dystonic movements of the forelimb), trunk-hindlimb
dystonia (including loose of postural reflexes) and locomotive
dyskinesias (small radius rotations contralateral to the lesion side)
were scored from 0 to 4 for each subtype, according to the time
and severity of each AIM (Lee et al., 2000). The maximum score
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included in the rating.
Spontaneous dyskinesias
Spontaneous behaviours were observed daily in the home cages
during 10min periods by researchers blinded to the experimen-
tal conditions. At baseline and 3, 7 and 18 weeks post-tx,
L-dopa-primed rats, were subjected to a stressful situation (hung
from the tail for 20s) and then placed in a transparent cylinder.
Stress-induced behaviour was recorded for 3min and sponta-
neously occurring dyskinetic behaviours were scored using the
AIMs scale. Observations during L-dopa phase were made 72h
after L-dopa administration.
LIDs
During a pre-transplantation induction period of 21 days rats
received daily intraperitoneal (IP) injections of L-dopa methyl ester
(12mg/kg, Sigma-Aldrich) combined with the peripheral dopa
decarboxylase inhibitor benserazide–HCl (15mg/kg, Sigma-
Aldrich). Baseline dyskinetic behaviours were scored at Day 21 of
L-dopa administration, and after a single L-dopa challenge 7 days
later. Rats with AIM scores520 were not used for transplantation.
Twelve weeks post-tx L-dopa treatment was reassumed. From weeks
12–15 post-tx animals received a daily dose of 6mg/kg of L-dopa
and 15mg/kg of benserazide (low dose), and at weeks 16 and 17a
daily dose of 12mg/kg and 15mg/kg of benserazide (high dose).
Higher L-dopa doses were not tested as it has been shown that doses
412mg do not elicit further dyskinesias in the 6-OHDA rat model
of PD (Lee et al., 2000). AIMs were rated once a week during the
low-dose phase and twice a week during the high-dose phase.
Apomorphine-induced dyskinesias
AIMs induced by apomorphine administration in L-dopa-primed
dyskinetic rats, were scored at 4 and 19 weeks post-tx using
the AIMs score. Two trained researchers, blinded to the experi-
mental conditions, observed the rats over 2-min periods 5, 15, 30
and 45min post injection. The first three observations were made
with the rats in the plastic bowls used for apomorphine-induced
rotations, and the last one was done in the home cage.
Contraversive rotations were only scored at the home cage
45min post injection.
VM dissection, cell suspension preparation and
transplantation procedures
Homozygote breeding pairs (DATKO or littermate wild-type)
were used for each experiment. E12.5 pregnant females were
Fig. 1 Experimental design. 6-OHDA rats, non-primed (cell dose study), or primed with L-dopa (dyskinesia study), were used. According
to baseline behavioural evaluations, rats were randomly allocated into three groups to receive wild-type or DATKO grafts, or saline.The
effects of transplantation in parkinsonism (cell dose and dyskinesia studies), and L-dopa induced dyskinesias (dyskinesia study), were studied
beginning 4 weeks post-tx. In a parallel experiment, 6-OHDA-lesioned rats were used to analyse the effects of both graft types in striatal
extra-cellular DA levels.
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tal (60mg/kg, Sigma, MO), and VM dissection and cell suspension
preparation were carried out as previously described (Haque et al.,
1997). A confirmatory PCR was carried out with the remaining
tissue from each embryo used for transplantation.
Rats were pre-anaesthetized with an i.m injection of acepro-
mazine/atropine sulphate (3.3mg/kg, Boehringer Ingelheim
Vetmedica and 0.2mg/kg, Phoenix Scientific, respectively), and
anaesthetized with i.m injection of ketamine/xylazine (60mg/kg,
Fort Dodge and 3mg/kg, Phoenix Scientific, respectively). Rats
were placed in a Kopf stereotaxic frame (Kopf Instruments) and
VM cell suspension or vehicle (HBSS-glucose 0.2% DNAse) was
injected in four deposits distributed in 2 AP tracts, using a
22-gauge, 10ml Hamilton syringe. From bregma: (i) AP+0.4,
L 3, V 5.5 and 4.5; (ii) AP  0.5, L 3.6, V 5.5 and 4.5.
In the cell dose transplantation study, a group of rats (n=24)
received a total of 135000 DATKO or wild-type VM cells or
vehicle (‘Low cell dose’). An additional group (n=14) received
500000 DATKO or wild-type VM cells (‘High cell dose’). In the
dyskinesia transplantation study (n=24) 6-OHDA lesioned rats,
dyskinetic after chronic treatment with L-dopa, received 250000
wild-type or DATKO VM cells or vehicle. Starting the day before
surgery, rats were immunosuppressed with subcutaneous injec-
tions of cyclosporine A (15mg/kg/day, Sandimmune; Sandoz,
East Hannover, NJ). Eight weeks post-tx the dose was reduced to
12mg/kg/day.
In vivo microdialysis and HPLC
Twenty 6-OHDA lesioned rats were grafted with 250000 wild-type
or DATKO cell suspensions using the same coordinates described
above. Eight weeks post-tx, graft survival was assessed by
amphetamine and paw-reaching tests. Rats showing graft-
mediated behavioural recovery, and 6-OHDA-lesioned controls
were used for in vivo microdialysis. Ten weeks post-tx, two dialysis
probes (3mm membrane length, 0.24mm external diameter,
Cuprophane, 6kDa cut-off, CMA-11; CMA/Microdialysis, Solna,
Sweden) were attached to the stereotaxic frame with the tips
separated by 2mm and implanted into the grafted striatum.
The posterior probe was implanted lateral and anterior to the
posterior graft at coordinates AP 0, M-L 4, D-V 6.5 relative to
bregma. The anterior probe was implanted 2 mm anterior to the
posterior probe (1.6mm anterior and 1mm lateral to the anterior
graft). Twenty-four hours after surgery, the dialysis probes were
connected to a syringe pump and perfused with artificial
cerebrospinal fluid (aCSF) (NaCl 147mM, KCl 2.7mM, CaCl2
1.2mM, MgCl2 0.85mM; CMA Microdialysis). To reliably
determine the basal extra-cellular DA levels in the striatum of
freely moving rats a quantitative ‘low perfusion’ rate microdialysis
experiment was conducted (Gainetdinov et al., 2003). After an
equilibration period for at least 1h, the perfusate was collected at
a perfusion rate of 0.1ml/min every 60min into collection tubes
containing 2ml of 0.5N perchloric acid. To analyse the effects of
amphetamine and L-dopa on the extra-cellular DA levels in
striatum, a ‘conventional’ microdialysis method (perfusion flow
rate 1ml/min) in freely moving animals was employed 48h after
surgery (Gainetdinov et al., 2003). In these experiments, dialysis
probes were equilibrated for 1h using 1ml/min CSF perfusion and
samples were collected every 20min into collection tubes
containing 2ml of 1N perchloric acid. At this perfusion rate,
three samples were collected as baseline, six samples after IP
injection of saline solution and six samples after IP injection of
amphetamine 4mg/kg. The same procedures were repeated in a
separate group (n=8) of 6-OHDA-lesioned, DATKO grafted
animals and 6-OHDA-lesioned controls and 48h after probe
implantation, the perfusate was collected every 20min at 1ml/min,
for 1h before and 3h after IP injection of L-dopa 12mg/
kg+Benserazide 15mg/kg.
Perfusate samples were assayed for DA and 3-methoxytyramine
using HPLC with electrochemical detection. DA was separated on
a microbore Unijet C18 reverse-phase column (C-18, 5lm,
1150mm; BAS, West Lafayette, IN, USA) with a mobile
phase consisting of 0.03M citrate–phosphate buffer with 2.1mM
octyl sodium sulphate, 0.1mM EDTA, 10mM NaCl and 17%
methanol (pH 3.6) at a flow rate of 90ml/min and detected by a
3-mm glass carbon electrode (Unijet; BAS) set at+0.8V. The
injection volume was 5ml. The sensitivity of the method permitted
detection of 3 fmol DA.
Post-mortem analyses
Rats were terminally anaesthetized by an IP injection of sodium
pentobarbital (100mg/kg) and intracardially perfused with ice-
cold heparin saline (0.1% heparin in 0.9% saline) followed by 4%
paraformaldehyde. Immunohistochemistry and stereological pro-
cedures were performed as in Redmond et al., 2008 (see
Supplementary material). For the analysis of fosB/fosB and
pDARPP-32 (Thr34) expression, two sections were analysed
(AP+0.4 and 0.5) from 6-OHDA-lesioned, dyskinetic, grafted
(wild-type and DATKO) and non-grafted animals. Two images
form equivalent dorsolateral and dorsomedial striatal locations
were taken from each section at either 20(pDARPP-32) or
40(fosB/fosB), and equivalent images were taken from the
contralateral, non-lesioned striatum. Quantification of fosB/fosB
and pDARPP-32 optical density (OD) was performed using NIH
image 1.61 software.
In situ hybridization studies were performed as previously
described (Henry et al., 1999) (see Supplementary material).
Receptor-binding studies
Fresh-frozen brains were cut into coronal sections (10mm thick)
using a cryostat (ThermoShandon) at 20C onto Superfrost
slides (Fisher Scientific, Hampton, NH). Slides were kept at
30C for 1–3 months prior to use in autoradiography
experiments. In the following experiments, three slides (nine
sections) were used per animal from the striatal region containing
the graft, for each binding assay. Experiments were performed as
previously described (Cha et al., 1999) (see Supplementary
material).
Results
Transplantation of foetal VM cell suspensions
from wild-type and DATKO mice into
non-L-dopa-primed 6-OHDA-lesioned rats
In the first experiment, 135 000 VM cells were grafted per rat.
Both wild-type and DATKO transplantation groups showed
a progressive recovery in apomorphine-induced con-
tralateral rotations that reached significance versus controls
at 12 weeks post-tx, without significant differences between
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see figure legends). Both wild-type and DATKO grafted
rats showed significant recovery on amphetamine-induced
ipsilateral rotations compared to controls, that started at 4
weeks post-tx and were maintained for the entire follow-up
period (Fig. 2A, P50.05). Rats grafted with wild-type cells,
but not those grafted with DATKO cells, showed a complete
recovery of ipsilateral rotations at 8 and 12 weeks post-tx.
After these ‘low cell dose’ transplantation, contralateral
rotations were present in wild-type but not in DATKO
Fig. 2 Behavioural effects of wild-type and DATKO grafts in 6-OHDA-lesioned rats. (A) Low cell dose (125 000 cells/host). Both graft
types significantly reduced apomorphine-induced rotations at12 weeks post-tx (one-way ANOVA and Tukey^Kramer multiple compari-
sons test). Both graft types significantly reduced amphetamine induced rotations at all time points tested, and wild-type grafts reduced
rotations significantly more than DATKO grafts,12 weeks post-tx (one-way ANOVA and Tukey^Kramer multiple comparisons test). Both
grafts improved significantly the use of the contralateral forepaw in the cylinder test. (B) High cell dose (500 000 cells/host). Both graft
types significantly reduced apomorphine induced rotations, and improvement of apomorphine-induced rotations was larger in DATKO
grafted animals than in wild-type grafted animals12 weeks post-tx (one-way ANOVA and Tukey^Kramer multiple comparisons test).Both
graft types significantly reduced amphetamine induced rotations at all time points tested, but only wild-type grafted animals showed an
on-average preference for turning contralateral to the lesioned hemisphere.Both grafts significantly improved the use of the contralateral
forepaw in the cylinder test. Significance in grafted versus controls
aP50.05;
bP50.01;
cP50.005.
P50.05 in wild-type versus DATKO
grafted animals.
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transplantation groups was significant at 12 weeks post-tx
(Fig. 2A, P50.05). Spontaneous motor activity evaluated
with the paw-reaching test showed a significant improve-
ment in the use of the contralateral forepaw in both the
wild-type and the DATKO transplantation groups, 12 weeks
post-tx (Fig. 2A, P50.05). No spontaneous dyskinesias were
observed in any of the grafted rats during daily observations
or in stress-induced tests (see Materials and methods
section).
A second group of 6-OHDA-lesioned rats were grafted
with 500000 wild-type or DATKO cells, to simulate
conditions with a larger number of DA neurons and
presumably higher level of extra-cellular DA. DATKO
grafted rats showed a significant improvement in apomor-
phine-induced contralateral rotations versus control rats
that started 4 weeks post-tx, and became complete 12 weeks
post-tx (Fig. 2B, P50.05). Wild-type grafted animals, on
the other hand, did not show a significant recovery until
8 weeks post-tx, with a maximum improvement of 60%.
The difference between transplantation groups was sig-
nificant at 12 weeks post-tx (Fig. 2B, P50.05). Wild-type
grafted animals showed a complete recovery of ampheta-
mine-induced rotations, and on average a preference to
rotate towards the contralateral unlesioned hemisphere, at
all post-tx times tested (Fig. 2B, P50.05). In contrast,
DATKO grafted rats significantly improved amphetamine-
induced rotations but contralateral rotations were almost
absent (Fig. 2B, P50.05, and Supplementary Fig. 1). Both
wild-type and DATKO grafted rats normalized their use of
the contralateral forepaw during the cylinder test performed
12 weeks post-tx (Fig. 2C, P50.05). Even after transplanta-
tion of 500000cells/rat, no spontaneous dyskinetic beha-
viours were observed in any of the groups at any of the
observation time points.
Transplant ation of fo e t al VM cell
suspensions from wild-type and DATKO
mice into 6-OHDA-lesioned, L-dopa-primed
dyskinetic rats
Based on the above studies, a cell dose of 250000cells/host
was chosen as appropriate for the rest of the study.
6-OHDA-lesioned rats rendered dyskinetic and grafted
with both wild-type and DATKO cells showed significant
recovery in apomorphine and amphetamine-induced rota-
tions compared to control rats, at all time points studied
(Fig. 3, P50.05). Similar to the results in non-dyskinetic
rats, DATKO grafts, but not wild-type grafts induced a full
recovery of apomorphine-induced rotations at 12 weeks
post-tx (Fig. 3, P50.05). Both wild-type and DATKO
grafted animals showed significant reductions of ampheta-
mine-induced rotations at all time points studied, but the
reduction in wild-type grafted animals was significantly
more pronounced than in DATKO grafted animals,
including an on-average preference for turning
contralateral to the lesioned hemisphere (Fig. 3, P50.05
and Supplementary Fig. 1). Evaluations 19 weeks post-tx
showed that the recovery of motor asymmetries after
apomorphine and amphetamine administration was not
altered by post-tx L-dopa treatment (Fig. 3).
Fig. 3 Behavioural effects of wild-type and DATKO grafts in
6-OHDA-lesioned, L-dopa-primed rats. Both graft types signifi-
cantly reduced apomorphine induced rotations at all time points
(one-way ANOVA and Tukey^Kramer multiple comparisons test).
Both graft types significantly reduced amphetamine induced rota-
tions at all time points, and the reduction in wild-type grafted
animals was significantly larger than that in DATKO grafted
animals (one-way ANOVA and Tukey^Kramer multiple compari-
sons test).Wild-type grafted animals showed a bias towards the
contralateral unlesioned hemisphere in all time points. Both grafts
improved significantly the use of the contralateral forepaw in the
cylinder test.
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in 6-OHDA-lesioned, L-dopa-primed,
dyskinetic rats
No spontaneous dyskinetic events were observed during
daily observations. In the evaluation of spontaneous
dyskinesias at 3, 7 and 18 weeks post-tx (see Materials
and methods section), rats that received wild-type and
DATKO cells showed, 3 weeks post-tx, very mild (53/16 in
AIM score) dyskinetic behaviours (mainly rotational
behaviours) that were not different from those shown by
vehicle injected rats at the same times of evaluation
(Fig. 4C). During apomorphine tests 4, and 19 weeks
post-tx, wild-type and DATKO grafted rats showed
significantly fewer dyskinesias than surgical controls at
both time points, without significant differences between
the two transplantation groups (Fig. 4C).
LIDs were studied using two doses: 6 and 12mg/kg (the
L-dopa dose used as pre-tx baseline). There was a significant
recovery in LIDs in both transplantation groups compared
to sham surgical control rats using both L-dopa doses, with
improvements in all dyskinetic behaviours analysed except
for orolingual dyskinesia (Fig. 4A and B). Similarly to
what is observed in Parkinson’s disease patients, there was
a significantly different effect of the two doses in the
generation of LIDs post-tx, shown by the significantly lower
dyskinesias induced by 6mg/kg of L-dopa compared to
12mg/kg, in the three experimental groups (Fig. 4A, ‘dose
effect’ t student P50.001). Interestingly, improvement
in LIDs was larger in rats grafted with wild-type cell
suspensions than in rats grafted with DATKO cell
suspensions for both L-dopa doses tested (Fig. 4A). By
symptoms, forelimb choreic movements after both L-dopa
doses and trunk dystonic movements after 6mg/kg of
L-dopa were significantly more reduced in wild-type than in
DATKO grafted rats (Fig. 4B).
Effects of foetal VM cell transplantation
on extra-cellular striatal DA levels
In 6-OHDA-lesioned rats that received sham surgery, basal
extra-cellular striatal DA levels were, on average, 3.45
0.28nM (3.630.38nM in anterior probe and 3.26
0.48nM in posterior probe; Supplemantary Fig. 2) as
determined by quantitative ‘low perfusion rate’ microdia-
lysis approach (Fig. 5B). Basal extra-cellular DA levels
in 6-OHDA-lesioned rats grafted with 250 000 wild-type
cells were, on average, 11.50.7nM (10.380.38nM
in anterior probe; 12.630.94nM in posterior probe;
Supplementary Fig. 2), a 3-fold increase compared to basal
levels of 6-OHDA-lesioned surgical controls (Fig. 5B).
Transplantation of 250 000 DATKO cells induced a 10-fold
increase in basal extra-cellular DA levels in the striatum
compared with surgical controls (33.65.2nM. Fig. 5B,
P50.001; 29.228 in anterior probe and 38.065.8 in
posterior probe; Supplementary Fig. 2). These levels were
3-fold higher than basal extra-cellular DA levels measured
in the striatum of wild-type grafted animals (Fig. 5B,
P50.05). In conventional microdialysis experiments, injec-
tion of amphetamine 4mg/kg caused an 2-fold increase in
6-OHDA-lesioned surgical controls (Fig. 5C), and a 4-fold
increase in rats that received wild-type cells, whereas rats
that received DATKO cells did not show a significant
increment in extra-cellular DA compared to saline injection
(1.2-fold, Fig. 5C). In a parallel experiment, administration
of 12mg/kg of L-dopa induced a 24-fold increase in extra-
cellular DA levels of DATKO grafted rats that returned to
baseline levels 180min post-injection. 6-OHDA-lesioned
surgical controls showed a 4-fold increase in extra-cellular
DA levels that lasted for 120min (Fig. 5C). Striatal trans-
plantation of a mixture of wild-type and DATKO cells
(35–65%, respectively), induced an increase in basal and
amphetamine-induced DA levels, between those found in
wild-type and DATKO grafted rats (data not shown),
demonstrating a gene dose dependence of these graft-
induced extra-cellular DA increases. Measures of the extra-
cellular DA metabolite 3-methoxytyramine (3-MT) in
striatal perfusates of all experimental groups showed similar
changes to those seen in extra-cellular DA. Extracellular
levels of 3-MT were on average 8.61.2nM in sham
surgical controls, whereas animals grafted with wild-type
and DATKO cells showed 3.5- (327.5nM) and 7-fold
(6315.7nM) increases in extra-cellular 3-MT, respectively
(Fig. 5B). These levels of 3-MT were significantly higher in
DATKO grafted animals than in sham surgical controls
(Fig. 5B, P50.05). These results are in agreement with
previous studies in DATKO mice that demonstrated that
extra-cellular 3-MT levels reflect extra-cellular DA levels,
and that both are increased in DATKO mice (Gainetdinov
et al., 2003).
Post-mortem analyses
Histological analysis of the grafts
Rats from cell dose and dyskinesia transplantation studies
were sacrificed 12 and 19 weeks post-tx, respectively
(Fig. 1). Post-mortem analysis of both wild-type and
DATKO grafts showed slender, well-integrated grafts
extending dorso-ventrally and reinervating adjacent striatal
areas (Fig. 6B and C). There were no differences in graft
location analysed as distance from bregma, and accord-
ing to its dorso-ventral and medio-lateral locations
(Supplementary Fig. 3). Stereological estimations of graft
volume, and optical density of TH-immunoreactive (-ir)
striatal reinervation did not show significant differences
between transplantation groups (Fig. 6E). Similarly,
stereological estimations of the number of surviving
TH-ir neurons in the grafts revealed no significant
differences between wild-type and DATKO grafted
animals (6320884 for wild-type versus 5121643 for
DATKO, P=0.28, Fig. 6E). Both DATKO and wild-type
grafts had the typical morphology of foetal VM grafts,
Transplanted DATKO DA neurons improve LID Brain (2008),131, 3361^3379 3367Fig. 4 Effects of wild-type and DATKO grafts in LID. (A) Both wild-type and DATKO grafts induced a significant recovery of LID at both
L-dopa doses tested (one-way ANOVA and Tukey^Kramer multiple comparisons test.Wild-type and DATKO versus vehicle P50.001).
Wild-type grafts reduced LID significantly more than DATKO grafts with both L-dopa doses tested (P50.05). (B) Both graft types signifi-
cantly improved forepaw, trunk-hindlimb and locomotive dyskinesias but not orofacial dyskinesias compared to surgical controls (one-way
ANOVA and Tukey^Kramer multiple comparisons test. Forelimb and findlimb P50.01 versus vehicle; Locomotive wild-type versus vehicle
P50.001, DATKO versus vehicle P50.05 for 6 mg/kg and P50.01for12mg/kg).Wild-type grafts improved forepaw dyskinesias (6 and
12mg/kg doses) and trunk-hindlimb dyskinesias (6mg/kg dose) significantly more than DATKO grafts (one-way ANOVA and Tukey^
Kramer multiple comparisons test.Forelimb P50.001for 6mg/kg and P50.05 for 12mg/kg.Trunk-hindlinb P50.05) (C) In both transplan-
tation groups, very mild spontaneous dyskinesias were observed, that were not different from those seen in surgical controls. Dyskinetic
behaviours observed during the apomorphine test (four time points. Locomotive dyskinesias evaluated only in the last time point with
animals in their homecage. Scores 0^52), were milder in both graft groups compared with surgical controls (one-way ANOVA and
Tukey^Kramer multiple comparisons test).
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graft-host border, and some cell clusters located towards
the centre of the graft (Fig. 6D). Cell type analysis with
specific markers showed a similar distribution of
dopaminergic cell subpopulations within both graft
types, with A9-like dopaminergic neurons (TH+/Girk2+)
preferentially located in the graft-host border and A10-
like (TH+/Calb+) dopaminergic neurons preferentially
Fig. 5 Changesin striatal extra-cellular DA measuredbyin-vivo microdialysis. (A) Schematic representation of probes andgrafts placement
in the microdialysis experiments. (B) Basal extra-cellular levels of DA and 3-methoxytyramine (3-MT) measured in striatal perfusates of
freely moving rats.Data are expressed as meanSEM of samples from both anterior and posterior probes. Samples were obtained every
60min during 6h, at a 0.1ml/min perfusion rate.
P50.05 wild-type versus controls, P50.001DATKO versus controls, fP50.05 DATKO
versus wild-type (Kruskal^Wallis and Dunn’s multiple comparisons test). (C) DA extra-cellular levels after amphetamine injection (4mg/kg
i.p) were obtained every 20min for 2h at1ml/min perfusion rate. Amphetamine induced a significant increase in extra-cellular DA levels in
wild-type grafted animals, whereas no increases were seen in DATKO grafted animals (repeated measures ANOVA and Tukey^Kramer
multiple comparison’s test). DA extra-cellular levels after L-dopa injection (12mg/kg i.p), were obtained every 20min for 3h at 1ml/min.
L-dopa induced a significantly larger increase in extra-cellular DA levels in DATKO grafted animals than in 6-OHDA-lesioned surgical
controls (Kruskal^Wallis and Dunn’s multiple comparisons test).
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Serotoninergic neurons were present in both wild-type
and DATKO grafts, with a tendency to be located in
central areas of the graft. In both types of grafts
serotoninergic neurons were 35% of all monoaminergic
neurons (32.50.41 for wild-type and 37.90.53 for
DATKO grafts. Fig. 6D and E).
There was a regional specific increase in fosB/fosB
expression in the denervated striatum of 6-OHDA-lesioned,
L-dopa-primed rats compared with the unlesioned striatum.
Fig. 6 Immunohistochemical analysis of wild-type and DATKO striatal grafts. (A^C) Low-magnification photomicrographs of coronal
sections immunostained withTH at different AP levels, showing the location of surviving grafted dopaminergic neurons and DA striatal
reinnervation. (D) Left panels show high-magnification photomicrographs of foetal grafts from boxes in B and C. In right panels, repre-
sentative photomicrographs from double immunofluorescence stainings showing the distribution of dopaminergic and 5-HT neurons within
the grafts. Scale bar=100mm. (E) Stereological analyses showed no difference in graft sizes, striatal innervation (measured byTH-OD),
surviving dopaminergic neurons and percentage of 5-HT neurons (from total number of monoaminergic neurons in the grafts), between
wild-type and DATKO grafts (NS=non-significant. Student t-test P40.05).
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DA-depleted, L-dopa-primed, sham surgery controls there
was a 2-fold increase in the OD of fosB/fosB immuno-
reactivity compared to the unlesioned striatum (Fig. 7).
Both graft types significantly reduced this increase in
fosB/fosB immunoreactivity in the dorsolateral striatum
(one-way ANOVA and Tukey–Kramer post hoc test,
P50.005, Fig. 7). There were no differences in the
reduction of fosB/fosB immunoreactivity between wild-
type and DATKO grafted animals (Fig. 7).
Analysis of p-DARPP-32 (Thr34) immunostaining also
revealed an increase in the denervated striatum of
6-OHDA-lesioned, L-dopa-primed rats compared with
the unlesioned striatum (+20%) (Supplementary Fig. 4).
Both graft types significantly reduced this increase
in the dorsolateral striatum (one-way ANOVA and
Fig. 7 Analysis of FosB/fosB striatal expression. High-magnification photomicrographs of fosB/fosB immunostaining from
6-OHDA-lesioned, dyskinetic animals, grafted with wild-type, DATKO and surgical controls.Two sections were analysed per animal
(AP +0.4 and ^0.5). Photomicrographs (40) from dorsolateral and dorsomedial striatum were obtained form grafted and unlesioned
sides and the OD of fosB/fosB immunoreactivity was quantified.Values are expressed as percentage of contralateral unlesioned side.
P50.05.One-way ANOVA and Tukey^Kramer multiple comparisons test.
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P50.05 DATKO graft). There was no difference in the
reduction of p-DARPP-32 immunostaining between wild-
type and DATKO grafted animals (Supplementary Fig. 4).
Receptor binding autoradiography
Analysis of DAT receptor binding demonstrated a complete
reduction of specific binding in the lesioned striatum of
6-OHDA-lesioned rats (data not shown). Specific binding
for DAT was observed in the grafted striatum of rats grafted
with wild-type cells, but not in DATKO grafts, consistent
with an absence of DAT expression in cells derived from
DATKO mice (data not shown).
DA D1, D2 and NMDA-receptor binding sites were
quantitatively analysed in the ipsilateral and contralateral
striata in the following groups of rats: unlesioned,
6-OHDA-lesioned, 6-OHDA-lesioned receiving wild-type
or DATKO grafts, L-dopa-treated 6-OHDA-lesioned dyski-
netic rats and 6-OHDA-lesioned dyskinetic rats receiving
wild-type or DATKO transplants. Densitometric analysis
was performed in the whole striatum, dorso-lateral,
medio-lateral, ventro-lateral and ventro-medial quadrants
and at increasing distances away from the graft-host border.
The results are summarized in Supplementary Table 1.
DA D1receptors
Following 6-OHDA-lesioning alone or 6-OHDA-lesioning
and L-dopa priming, there was no change in DA D1
receptor-binding sites in the whole striatum compared with
unlesioned animals. In dyskinetic 6-OHDA-lesioned rats
that received either wild-type or DATKO grafts, DA D1
receptors in the whole striatum were significantly decreased
compared to ungrafted dyskinetic 6-OHDA-lesioned ani-
mals (17%, P50.001, wild-type graft; 19%, P50.001,
DATKO graft; Fig. 8 and Supplementary Table 1A).
Analysis of DA D1-binding sites adjacent to or further
away from the graft border in dyskinetic rats grafted with
DATKO cells showed that D1 receptor-binding sites were
significantly reduced at all distances measured [0–800mm
(P50.001), 800–1600mm( P50.001) and 1600–2400mm
(P50.05)] compared with the unlesioned contralateral
side. In comparison, in the wild-type-grafted striatum,
Fig. 8 Changes in DA D1receptors in the grafted striatum.Pseudo-colour transformations of autoradiographs of DA D1receptor binding,
in 6-OHDA-lesioned animals and 6-OHDA-lesioned+ L-dopa, following grafting with either wild-type or DATKO VM cells. Receptor-
binding sites at distances adjacent to or further away from the graft border were quantified and each distance was compared with the
contralateral unlesioned side (
P50.05,
P50.01,
P50.0001, unpaired t-test).
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800–1600mm( P50.01) (Fig. 8 and Supplementary
Table 1A).
A comparison of the degree of reduction of DA D1
receptor-binding sites between wild-type and DATKO-
grafted striatum at distances adjacent to or further away
from the graft border (data expressed as percentage of
contralateral side) demonstrated that there was a signifi-
cantly greater reduction in DATKO-grafted striatum
compared to wild-type-grafted striatum at 800–1600mm
(P50.05) in dyskinetic grafted animals (Fig. 8 and
Supplementary Table 1A). Similar changes were observed
in 6-OHDA-lesioned, non-L-dopa-primed rats (see Supple-
mentary material).
DA D2 receptors
Following 6-OHDA-lesioning alone or 6-OHDA lesion
and L-dopa priming, there was no alteration in DA D2
receptor-binding sites in the whole striatum (Fig. 9 and
Supplementary Table 1B). In dyskinetic L-dopa-treated
6-OHDA-lesioned rats receiving wild-type or DATKO
grafts, DA D2 receptor-binding sites in the whole striatum
were significantly decreased compared to ungrafted dyski-
netic surgical controls (19%, P50.01, wild-type graft;
26%, P50.001, DATKO graft) (Fig. 9 and Supplementary
Table 1B). Analysis of DA D2-binding sites adjacent to and
further away from the graft border in dyskinetic rats grafted
with DATKO cells, showed that D2 receptor-binding sites
were significantly reduced compared to the contralateral
side of the same animals at 800–1600mm( P50.05) (Fig. 9
and Supplementary Table 1B). In comparison, in the wild-
type-grafted striatum, D2 receptor-binding sites were
unchanged.
A comparison of the reduction of DA D2 receptor-
binding sites between wild-type and DATKO-grafted
striatum (data expressed as percent of contralateral side),
showed that there was a significantly greater reduction in
DATKO than wild-type-grafted striatum at 800–1600mm
(P50.05) in dyskinetic animals (Fig. 9 and Supplementary
Table 1B). Similar changes were observed in 6-OHDA
lesioned, non- L-dopa-primed rats (see Supplementary
material).
Fig. 9 Changes in DA D2 receptors in the grafted striatum. Pseudo-color transformations of autoradiographs of DA D2 receptor binding
in 6-OHDA-lesioned animals and 6-OHDA-lesioned+ L-dopa, following grafting with either wild-type or DATKO VM cells. Receptor-
binding sites at distances adjacent to or further away from the graft border were quantified and each distance was compared with the
contralateral unlesioned side. (
P50.05,
P50.01,
P50.0001, unpairedt-test).
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In 6-OHDA-lesioned animals, NMDA glutamate receptor-
binding sites in the whole striatum were significantly
increased (+18%, P50.05) compared to unlesioned animals
(Supplementary Table 1C and Supplementary Fig. 5). In
L-dopa-treated dyskinetic animals that received either
wild-type or DATKO grafts, NMDA receptors in the
whole striatum were significantly reduced compared to
6-OHDA-lesioned, dyskinetic surgical controls (9.1%,
P50.001, wild-type graft; 14%, P50.001, DATKO graft;
Supplementary Table 1C and Supplementary Fig. 5).
Analysis of NMDA receptor-binding sites adjacent to and
further away from the graft border in dyskinetic rats grafted
with wild-type or DATKO cells showed that NMDA
receptor-binding sites were significantly reduced compared
to 6-OHDA-lesioned, dyskinetic surgical controls at
0–800mm and 800–1600mm( P50.01 for 0–800mm and
800–1600mm in wild-type grafted animals, and P50.01 for
0–800mm and P50.001 for 800–1600mm in DATKO
grafted animals; Supplementary Table 1C and Supplemen-
tary Fig. 5).
A comparison of NMDA receptor-binding sites between
wild-type and DATKO-grafted striatum (data expressed as
percentage of contralateral side) showed that there was
no significant difference between wild-type and DATKO-
grafted striatum in L-dopa-treated dyskinetic rats (Supple-
mentary Table 1C and Supplementary Fig. 5).
PEnk mRNA expression
Densitometric analysis of PEnk mRNA expression was
performed in a similar manner to the receptor-binding
studies. In L-dopa-primed 6-OHDA-lesioned rats grafted
with either wild-type or DATKO-grafted animals,
PEnk mRNA expression was significantly reduced com-
pared to 6-OHDA-lesioned, L-dopa-primed, ungrafted
animals (55%, P50.01, wild-type-graft; 49%, P50.05,
DATKO-graft) (Supplementary Table 1D). Analysis of PEnk
mRNA expression adjacent to and further away from the
graft border in L-dopa-treated dyskinetic rats grafted with
either wild-type or DATKO cells showed that they were
significantly reduced compared to 6-OHDA-lesioned,
dyskinetic surgical controls at the three distances analysed
(P50.01 for both wild-type and DATKO grafted animals;
Fig. 10 and Supplementary Table 1D).
A comparison of the reduction of mRNA expression
between wild-type and DATKO-grafted striatum (data
expressed as per cent of contralateral side) showed that
there was no significant difference in L-dopa-treated
dyskinetic rats receiving wild-type- and DATKO-grafts at
any of the distances analysed.
Discussion
The study provides several major findings: (i) striatal
transplantation of foetal VM tissue as a cell suspension
improves both parkinsonism and LID in a 6-OHDA rat
model of Parkinson’s disease; (ii) drug induced behavioural
tests showed a more complete normalization of DA
receptor supersensitivity in DATKO grafted animals than
in wild-type grafted animals, that was confirmed by
receptor-binding studies; (iii) DATKO grafts produced
large increases in extra-cellular DA levels throughout the
denervated striatum that were 3-fold higher than those
produced by wild-type grafts, and 10-fold higher than
extra-cellular DA levels in denervated controls; (iv) DATKO
grafts did not induce spontaneous dyskinesias and did
not worsen the severity of previously present LID, demo-
nstrating a lack of effect of high DA tone on LIDs. Both
graft types reduced LID compared with sham surgical
controls. Interestingly, grafts containing wild-type dopami-
nergic neurons reduced LID more than grafts containing
DATKO dopaminergic neurons; and (v) Both wild-type and
DATKO grafts induced a similar downregulation of PEnk,
fosb/fosb and NMDA in striatal neurons of lesioned,
L-dopa-primed dyskinetic rats. These conclusions and find-
ings are discussed in detail below.
Integration of foetal VM grafts in the
denervated striatum
Neural transplantation provides a new approach to
Parkinson’s disease therapy based on the idea that new
neurons can provide functional neurotransmission and
structural reconstruction of circuitry. DA replacement by
neural transplantation is produced by newly generated
terminals of grafted neurons into the denervated striatum,
which contrast with the classic pharmacological approaches
based on the unregulated effects of dopaminergic dugs
in the striatum. Early work in the field demonstrated
that foetal donor neurons can orient axonal growth
towards their normal synaptic targets due to the presence
of specific guidance cues in the adult host brain (Isacson
et al., 1995; Isacson and Deacon, 1996). More specifically,
recent studies in rats (Thompson et al., 2005), monkeys
(Redmond et al., 2008) and Parkinson’s disease patients
(Mendez et al., 2005) have shown that different types of
dopaminergic neurons (A9/SNc and A10/VTA neurons)
with specific distribution within foetal grafts are able to
reinervate their natural targets in the denervated striatum.
Moreover ultrastructural studies of synapses formed by
transplanted foetal dopaminergic neurons on host striatal
medium spiny neurons indicate that these new synapses
have a normal morphology and similar location within
medium spiny neurons, although compared to normal
striatum they show an increased tendency to be located
on dendritic shafts rather than on dendritic spines (Freund
et al., 1984, 1985; Bolam et al., 1987). Additionally, these
new terminals provide a hyperinnervation of striatal
cholinergic interneurons but it remains to be determined
whether such changes are detrimental, or possibly result
in a more efficacious synaptic transmission as postulated
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electrophysiological studies have revealed the presence of
normal pre- and post-synaptic control mechanisms in
these newly generated synapses (Zetterstrom et al., 1986;
Strecker et al., 1987; Fisher et al., 1991). As predicted by all
these observations, foetal cell transplantation has been
shown to reduce motor deficits in animal models (Perlow
et al., 1979; Bjorklund et al., 1982; Redmond et al., 2008)
and Parkinson’s disease patients (Freed et al., 1992;
Lindvall, 1998; Hauser et al., 1999; Piccini et al., 1999;
Mendez et al., 2005). Unexpectedly, recent double-blind
clinical trials in grafted Parkinson’s disease patients showed
cases of lack of efficacy and the occurrence of OFF-L-dopa
dyskinesias (Freed et al., 2001; Olanow et al., 2003). These
trials have revealed a need for in-depth studies of
the physiological and molecular changes caused by dopa-
minergic denervation and chronic L-dopa therapy, and the
effects of foetal grafts in this altered corticostriatal motor
circuitry.
Striatal DATKO and wild-type foetal
transplantation induce different
improvements of parkinsonian signs
Both graft types induced a full recovery of spontaneous
motor performance as demonstrated by the lack of side bias
in the paw-reaching test, but pharmacological tests showed
important differences in the functional impact of wild-type
as compared to DATKO grafts. Amphetamine administra-
tion in animals that received wild-type grafts induced a
marked reduction of the ipsilateral rotations seen pre-
transplantation, and the appearance of contralateral rota-
tions. In contrast DATKO grafted animals showed an
almost complete recovery of amphetamine-induced rota-
tions without the occurrence of overcompensatory con-
tralateral rotations (Supplementary Fig. 1). Microdialysis
experiments demonstrated a 4-fold increase in DA levels in
the wild-type grafted striatum after amphetamine admin-
istration. This is in agreement with previous studies of
Fig. 10 Changes in preproenkephalin in the grafted striatum. Pseudo-color transformations of in situ hybridization for preproenkephalin
(PEnk; PPE-A), in 6-OHDA-lesioned animals and 6-OHDA-lesioned+ L-dopa, following grafting with either wild-type or DATKO VM cells.
mRNA PEnk expression at distances adjacent to or further away from the graft border was quantified and compared to the expression in
6-OHDA-lesioned, dyskinetic surgical controls.In addition, receptor-binding sites and mRNA expression, presented as a percentage of the
unlesioned contralateral side, were compared between wild-type and DATKO grafted animals at distances near to and further away from
the graft border (
P50.05,
P50.01,
P50.0001, unpairedt-test).
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(Zetterstrom et al., 1986; Herman et al., 1993). As expected,
due to the need of DAT for amphetamine-mediated release
(Jones et al., 1998b), microdialysis experiments confirmed
that in DATKO grafted animals amphetamine admini-
stration induced a minimal increase of striatal DA. This
increase was of similar magnitude to that seen in dener-
vated controls and probably originated in the remaining
host terminals. Thus, as extra-cellular DA levels prior to
amphetamine were 3-fold higher in DATKO grafted
striatum; extra-cellular DA levels after amphetamine
administration were similar in both grafted groups
(Fig. 6). The overcompensatory rotational response in
wild-type grafted animals to amphetamine administration
reflects an excessive activity of the grafted striatum,
probably related to post-synaptic supersensitivity of non-
reinervated striatal neurons, that are stimulated by DA
released by the graft in response to amphetamine that
diffuses to non-reinervated striatal areas. The lack of
contralateral rotations in animals with DATKO grafted
neurons despite the presence of similar extra-cellular DA
levels compared to wild-type grafts, suggests that the high
DA levels created by DATKO grafts also reached non-
reinervated striatal areas producing a permanent reduction
of DA receptor supersensitivity in these areas. This
reduction in DA receptor supersensitivity seen in DATKO
grafted animals is most likely due to the increase in the
striatal volume covered by DA released by each terminal,
resulting in volume transmission as described in DATKO
mice (Jones et al., 1998a). Consistent with this, contral-
ateral rotations in response to the full DA agonist
apomorphine were significantly but not completely reversed
by wild-type grafts (60% reduction), whereas animals
grafted with DATKO cell suspensions showed an almost
complete recovery of contralateral apomorphine-induced
rotations. This indicates that wild-type VM grafts normalize
DA transmission in reinervated but not in non-reinervated
areas (as shown in Stromberg et al., 2000), whereas
DATKO grafts (that reinervated 40% of the denervated
striatum) normalized DA receptor activity beyond the
reinervated areas.
These differences between the effects of wild-type and
DATKO grafts in striatal DA receptors were in part
explained by receptor binding analysis of striatal DA D1
and D2 receptors, which showed that while both graft types
induced a significant downregulation of DA receptors
compared with denervated controls, DATKO grafts had a
more complete effect on DA receptors in areas around the
graft, and a larger area of DA receptor downregulation.
This effect on DA receptors was likely mediated both by DA
reinervation and by the high extra-cellular levels of DA
generated by the graft that reached non-reinnervated striatal
areas by volume transmission, and normalized the activity
of extrasynaptic DA receptors (Yung et al., 1995), and
subsequently also improved drug-induced behaviours. The
normalization of amphetamine- and apomorphine-induced
responses with partial recovery of LID seen in DATKO-
grafted animals (see below) indicates that this improve-
ment, mediated by diffusion of extra-cellular DA to distant
neurons, does not reflect a full structural and functional
recovery of corticostriatal transmission. Supporting this
idea, electrophysiological studies have shown partial nor-
malizations in DA receptor activity in areas not reinervated
by the grafts (Stromberg et al., 2000). Additionally, the
current work and other studies (Fisher et al., 1991; Lane
et al., 2006) show that foetal VM grafts can induce some
improvements in amphetamine-induced rotational behav-
iours before grafted foetal neurons fully reinervate striatal
neurons.
Both wild-type and DATKO grafts improved
LIDs and did not induce OFF-L-dopa
dyskinesias
OFF-L-dopadyskinesias
6-OHDA-lesioned rats not primed with L-dopa and grafted
with wild-type or DATKO cells did not show any sign of
OFF- L-dopa dyskinesias, even when 500000 cells were
grafted per animal. In the rat model of LID, fully
denervated animals show a high sensitivity to the fluctua-
tions of extra-cellular DA induced by L-dopa treatment
(Dethy et al., 1999), often showing dyskinetic behaviours
even after the first L-dopa dose (Winkler et al., 2002 and
Vinuela et al., unpublished data). This effect is even more
dramatic when L-dopa is administered directly in the
striatum of 6-OHDA-lesioned rats (Carta et al., 2006). In
the present study, the permanently high extra-cellular DA
levels produced by large DATKO grafts did not induce any
type of spontaneous dyskinesias. Moreover, the lack of
dyskinesias in animals grafted with large DATKO grafts,
with the subsequent high extra-cellular DA levels in areas
not reinervated by foetal DA fibres, supports the notion
that tightly regulated DA release from foetal grafts does not
produce spontaneous abnormal movements by itself.
A detailed study of spontaneous and stress-induced OFF-
L-dopa behaviours only revealed mild dyskinetic behaviours
during the first weeks post-tx and they were of the same
magnitude and distribution in the transplantation groups
and in L-dopa-primed sham surgical controls. Even during
the L-dopa treatment phase no spontaneous dyskinesias
were observed in any of the groups. In previous studies
of OFF- L-dopa dyskinesias and foetal VM transplantation
in this rat model, only one reported mild spontaneous
dyskinetic behaviours in the first weeks post-tx (Lane et al.,
2006), but after these early stages none of the studies
reported spontaneous dyskinesias (Lee et al., 2000; Steece-
Collier et al., 2003; Carlsson et al., 2006; Lane et al., 2006;
Maries et al., 2006). The occurrence of these early
dyskinetic behaviours is, most likely, related to processes
of cell maturation and integration and with surgery-
related events.
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foetal VM cell transplantation has been underscored by two
recent double-blind clinical trials testing the efficacy of fetal
VM cell transplantation as solid pieces into the striatum of
Parkinson’s disease patients (Freed et al., 2001; Olanow
et al., 2003). As a possible explanation for these dyskinesias,
it has been suggested that small grafts would produce ‘hot
spots’ of striatal DA reinervation, that would normalize
striatal supersensitivity in a limited area and at the same
time would give rise to a ‘spill-over’ of DA, released in a
non-regulated neuro-humoral manner (Freed et al., 2001;
Hagell and Cenci, 2005; Maries et al., 2006). This
unregulated DA release would reach supersensitive recep-
tors in striatal areas not reinervated by the graft and
generate abnormal movements. This possibility has been
also examined by transplantation studies in rodents that
linked this graft-mediated effect on supersensitive post-
synaptic terminals, with an incomplete focal pattern of
striatal reinervation by these grafts. In contrast, such ‘hot
spots’ described using PET (Ma et al., 2002), were not
correlated with the occurrence of OFF- L-dopa dyskinesias
in other clinical studies (Hagell et al., 2002). In the current
study, microdialysis demonstrated that high DA levels
released by DATKO grafts cover almost all striatum, also
involving striatal areas not reinervated by the graft.
Notably, this situation, which resembles a neurohumoral
DA release, did not elicit OFF- L-dopa dyskinesias. The lack
of dyskinesias and other behavioural changes in DATKO
grafted rats, despite the presence of high striatal extra-
cellular DA levels, contrast with the severe side-effects seen
in Parkinson’s disease patients after intraventricular injec-
tion of DA. These patients showed different combinations
of dyskinesias, myoclonic jerks, severe depression and
psychotic behaviours that disappeared when DA infusion
was discontinued (Venna et al., 1984). A similar response
has been reported in 6-OHDA-lesioned rats in which
intrastriatal infusion of L-dopa elicited LID even in non-
L-dopa-primed rats (Carta et al., 2006). In conclusion, our
findings indicate high extra-cellular DA levels produced by
striatal foetal grafts may not be responsible for the
generation of OFF- L-dopa dyskinesias, even when they
diffuse to non-reinervated striatal areas. Other aspects of
these trials related with the surgical technique or cell
preparation, and the striatal lesion and inflammation
induced by them, are more likely to be related with this
unexpected side-effect.
LIDs
Both graft types produced an overall reduction in LID
compared to sham surgical controls. These results, and
those of previous studies using wild-type rat cell suspen-
sions (Lee et al., 2000; Carlsson et al., 2006; Lane et al.,
2006; Maries et al., 2006) indicate that striatal foetal neural
transplantation reduces LID when sufficient striatal DA
reinervation and synaptic regeneration is achieved. In the
presence of local mechanisms of regulation of DA release,
presynaptic DA terminals from the graft take up L-dopa,
decarboxylate it to DA and in the case of wild-type
neurons, release it in a physiologically normal manner (see
our microdialysis data and Zetterstrom et al., 1986). This
contrasts with the situation in the denervated striatum
without transplants, where L-dopa is decarboxylated in
serotonin terminals, glial cells and blood vessels and DA is
released in a non-regulated way primarily as a function of
fluctuating levels of L-dopa, therefore exposing hypersensi-
tive post-synaptic terminals to pulsatile DA levels (Djaldetti
et al., 1996) leading to LID (Stocchi et al., 2005). Critical to
understanding the neurobiology of dyskinesia in the context
of DA transmission, dyskinesia reduction was also seen in
DATKO grafted animals, which emphasizes the possibility
that appropriate and complete striatal DA reinervation and
not DA extra-cellular levels is the key factor for functional
recovery and reduction of existing LID. New DATKO graft
derived DA terminal networks in the host striatum
re-establish synaptic function, yet DA levels are 10-fold
higher than in the striatum of 6-OHDA lesion alone, and
3-fold higher than in the wild-type grafted striatum. In this
situation of lack of reuptake, a dose of L-dopa induced a
dramatic increase of extra-cellular DA, that was more
pronounced than that seen in non-grafted denervated
animals (see Results section and Dethy et al., 1999).
Notably, wild-type grafts induced a significantly larger
reduction of LID compared to DATKO grafted animals,
which contrast with the broader and more complete down
regulation of DA receptors, amphetamine and apomorphine
tests by DATKO grafts. A possible explanation for this
difference between wild-type and DATKO grafts would be
that the neurotransmission provided by grafted wild-type
dopaminergic neurons is likely to be more precise, and
would have a more A9-(SNc-) like autoinhibition of DA
levels, similar to normal or homeostatic DA levels at the
terminals in the striatum, whereas DATKO neurons would
mimic an A10- (VTA-) like neurotransmission, given that
VTA dopaminergic neurons express both less DAT and D2
autoreceptors. Interestingly, dyskinesia reduction was linked
in both graft types to similar reductions of the abnormally
upregulated expressions of PEnk and fosB/fosB (that
parallels PDyn mRNA expression; Steiner and Gerfen, 1998;
Andersson et al., 1999), markers of the activity of indirect
and direct striatal output pathways, respectively. Both graft
types induced similar reductions in NMDA receptors in the
post-synaptic elements. This, and the fact that DATKO
grafts induce only a partial improvement of LID, support
the possibility that while DA alone is able to induce a
downregulation of DA receptor supersensitivity, the pre-
sence of new functional DA presynaptic terminals may be
necessary to revert the maladaptative synaptic plasticity
processes that occur in medium spiny neurons as a result of
dopaminergic denervation and chronic L-dopa treatment
that are related to the development of LID (Cenci et al.,
1998; Andersson et al., 1999; Calabresi et al., 2000;
Transplanted DATKO DA neurons improve LID Brain (2008),131, 3361^3379 3377Nash and Brotchie, 2002; Oh and Chase, 2002; Lundblad
et al., 2004; Pavon et al., 2006). Our results also emphasize
the therapeutic importance of reducing the impact of
pulsatile DA levels produced by L-dopa administration
(Stocchi et al., 2005) by providing local and regulated DA
transmission where available post-synaptic DA receptor
terminal function can compensate and prevent abnormal
transmission in the dendritic spines of striatal medium
spiny neurons, even in the absence of pre-synaptic reuptake
of DA. Notably, the presence in both graft types of 35%
of serotoninergic neurons did not lead to the worsening of
LID or to the occurrence of OFF-dyskinesia.
Based on these findings we propose that despite the
capacity of extra-cellular DA to correct many aspects of
striatal DA neurotransmission acting through extra-synaptic
sites, the presence of terminals from the dopaminergic
neurons that can regulate DA release locally provides a
more complete correction of the changes in the circuitry in
response to dopaminergic denervation and chronic L-dopa
treatment. In addition, the use of DA reuptake deficient
cells reveals that DA terminals from the grafts provide
functional recovery even in the presence of abnormally high
extra-cellular DA levels. These findings suggest that DA
terminals, and not DA levels per se, restore function in an
animal model of Parkinson’s disease.
Supplementary material
Supplementary material is available at Brain online.
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